Poltreg S.A.

Warsaw Stock Exchange PTG.WA

Poltreg S.A. EBIT for the year ending December 31, 2023: USD -3.22 M

Poltreg S.A. EBIT is USD -3.22 M for the year ending December 31, 2023, a -747.64% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Poltreg S.A. EBIT for the year ending December 31, 2022 was USD -380.25 K, a 58.42% change year over year.
Poltreg S.A. EBIT for the year ending December 31, 2021 was USD -914.56 K, a -341.34% change year over year.
Poltreg S.A. EBIT for the year ending December 31, 2020 was USD -207.22 K, a -2.41% change year over year.
Poltreg S.A. EBIT for the year ending December 31, 2019 was USD -202.35 K, a 4.41% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Warsaw Stock Exchange: PTG.WA

Poltreg S.A.

CEO	Mr. Piotr Trzonkowsk
IPO Date	Nov. 23, 2021
Location	Poland
Headquarters	Waly Piastowskie 1 lok. 1508
Employees	25
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.

Key trends

Past 5 years